Taylor Financial Group Inc. Buys 142 Shares of Johnson & Johnson (NYSE:JNJ)

Taylor Financial Group Inc. boosted its stake in Johnson & Johnson (NYSE:JNJ) by 5.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,631 shares of the company’s stock after acquiring an additional 142 shares during the quarter. Taylor Financial Group Inc.’s holdings in Johnson & Johnson were worth $436,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in JNJ. Highline Wealth Partners LLC lifted its stake in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. von Borstel & Associates Inc. acquired a new stake in Johnson & Johnson in the 1st quarter valued at about $49,000. Capital A Wealth Management LLC bought a new position in Johnson & Johnson in the 4th quarter valued at about $50,000. Harvest Fund Management Co. Ltd acquired a new stake in Johnson & Johnson during the first quarter worth approximately $52,000. Finally, Accredited Wealth Management LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth approximately $58,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Up 1.1%

Shares of JNJ opened at $173.40 on Friday. Johnson & Johnson has a one year low of $140.68 and a one year high of $173.96. The company has a market cap of $417.61 billion, a P/E ratio of 18.55, a P/E/G ratio of 2.18 and a beta of 0.41. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a 50 day simple moving average of $159.26 and a two-hundred day simple moving average of $157.44.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the previous year, the business earned $2.82 earnings per share. The company’s revenue was up 5.8% on a year-over-year basis. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Royal Bank Of Canada raised their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research report on Thursday, July 17th. Leerink Partners downgraded shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Raymond James Financial cut their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research report on Monday, April 14th. UBS Group raised their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, July 17th. Finally, Leerink Partnrs downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Nine research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $174.50.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.